维利西呱治疗心力衰竭的疗效和安全性分析！

Vericiguat can regulate endothelial function and myocardial energy metabolism through the nitric oxide cyclic guanosine monophosphate signaling pathway (NO-sGC-cGMP), improving the prognosis of HF patients. It is a soluble guanylyl cyclase (sGC) agonist. On January 20, 2021, the US FDA approved it for use in symptomatic chronic heart failure patients with ejection fraction <45% to reduce the risk of cardiovascular death and heart failure hospitalization after worsening heart failure events.

In a clinical trial, all patients were randomly assigned to the vericiguat 2.5 mg/d group or the placebo group in a 1:1 ratio after a screening period of 0 to 30 days. Based on the patient's blood pressure and clinical symptoms, the dose of vericiguat was gradually increased to the target dose of 10 mg/d. Median follow-up was 10.8 months.

The trial results showed that the incidence of the primary endpoint (the composite endpoint of death from cardiovascular causes or first hospitalization for heart failure) was 35.5% in the vericiguat group and 38.5% in the placebo group. Vericiguat reduced the risk of the primary endpoint event by 10%, with a hazard ratio HR (95% confidence interval CI) of 0.90. Combining the above tests, it can be seen that vericiguat can reduce the risk of death, improve the patient's quality of life and disease progression, have a positive effect on the patient's condition, and has a significant therapeutic effect.

Hypotension and anemia are the main side effects of veliciguat, and the overall safety profile is tolerable. It should be noted that Vericiguat may cause fetal harm. Do not take it to pregnant women. Pregnancy should be ruled out before starting treatment with this product. Concomitant use of PDE-5 inhibitors with vericiguat is not recommended, and breastfeeding is not recommended.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: